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Medicine, Fajara, The Gambia
Protective immunity to Mycobacterium tuberculosis (Mtb)—the causative agent of
tuberculosis (TB)—is not fully understood but involves immune responses within the
pulmonary airways which can lead to exacerbated inflammation and immune pathology.
In humans, this inflammation results in lung damage; the extent of which depends on
specific host pro-inflammatory processes. Neutrophils, though increasingly linked to
the development of inflammatory disorders, have been less well studied in relation to
TB-induced lung pathology. Neutrophils mode of action and their specialized functions
can be directly linked to TB-specific lung tissue damage observed on patient chest
X-rays at diagnosis and contribute to long-term pulmonary sequelae. This review
discusses aspects of neutrophil activity associated with active TB, including the resulting
inflammation and pulmonary impairment. It highlights the significance of neutrophil
function on TB disease outcome and underlines the necessity of monitoring neutrophil
function for better assessment of the immune response and severity of lung pathology
associated with TB. Finally, we propose that some MMPs, ROS, MPO, S100A8/A9 and
Glutathione are neutrophil-related inflammatory mediators with promising potential as
targets for developing host-directed therapies for TB.
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INTRODUCTION
Tuberculosis (TB) is the single deadliest infectious disease known to man with 10 million new
cases and 1.6 million deaths (including 300,000 HIV coinfected) in 2018 (1). This report does
not account for health impairment nor deaths during and following TB treatment; which is
suggested to be about three times higher than those observed in the general population or suitably
matched controls (2). It is known today that despite being diagnosed as microbiologically cured
from TB, about 50% of patients still suffer from some form of pulmonary impairment after
tuberculosis (PIAT), irrespective of smoking habits (3). The definition of PIAT encompasses several
clinical conditions; which in former TB patients is suggested to result from chronic inflammation,
characterized by disrupted pulmonary structure and function (residual lung deficits) (4, 5); a
state described as thoracic/TB sequelae (6). These include parenchymal, airway, vascular and
mediastinal lesions manifested mainly through structural [cicatrization, calcification, fibrosis and
reduction in cavity wall thickness (6)] and functional [deficit in forced expiratory volume (4)]
damage; the establishment (7) and severity (8–10) of which, are associated to neutrophil abundance
and (hyper-)activity.
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As compelling as these effects of TB may be, PIAT is presently
not included in global estimates of TB burden despite increasing
scientific interest and evidence of associated morbidity and
mortality (3–5, 11–14).
A recent cohort study showed that subjects with a history
of fully treated active TB (ATB) lost 3.6 years on average of
disability-adjusted life expectancy compared to subjects with
latent TB infection (LTBI) who did not progress to the active state
(12). Despite the lack of data to support disease burden resulting
from long-term sequelae (11), the above reduced life expectancy
is a direct result of TB sequelae and suggests that a considerable
proportion of the TB disease burden is contributed by subjects
who have successfully clearedMtb. Indeed, a study in Texas, USA
reported that the number of years lived with chronic TB disability
accounts for 75% of non-fatal health effects of TB (11). This same
study suggests that the most health and financial savings may
be achieved by preventing rather than shortening therapeutic
strategies. Additionally, a recent retrospective study reveals the
negative effect of drug-resistance and disease recurrence on PIAT
(15). Consequently, early detection of parameters which increase
the likelihood of ATB complication into chronic inflammation
and long-term sequelae would inform clinicians on the need for
case-specific treatment measures and contribute to minimizing
the global TB burden (13). Such parameters can be realistically
linked to neutrophil function and/or interaction with other
immune cell populations in the view of their specific activities
described in subsequent sections below.
Generally, protective immunity toMycobacterium tuberculosis
(Mtb)—the causative agent of TB—is a combination of
innate and adaptive immune responses within the pulmonary
airways via which this pathogen gains entrance into the
human host (16, 17). This immune response to TB is
described as a chronic granulomatous inflammation; caused
by close interaction between Mtb bacilli and host immune
agents at the infection site (18). Indeed, the term “chronic
granulomatous” draws from a condition, chronic granulomatous
disease (CGD), with similar inflammatory outcomes; resulting
from genetic mutations of reduced nicotinamide adenine
dinucleotide phosphate (NADPH2) oxidase-encoding genes (19,
20). Disruption in the production of this enzyme; which normally
catalyzes the synthesis of reactive oxygen species (ROS) used
by phagocytes to destroy bacteria during phagocytosis, leads to
enhanced susceptibility to infectious pathogens and granuloma
formation; particularly in the lungs (21). Despite several gaps
in knowledge, the contribution of adaptive immune responses:
particularly T-cells [reviewed in Jasenosky et al. (22)] and to a
lesser extent B-cells [reviewed in Achkar et al. (23)] have been
addressed. Furthermore Dyatlov et al. recently reviewed the role
of B cells on reducing neutrophil influx to infection sites (24)
and; these Mtb-specific immune responses having been studied
extensively and will not form a focus of this review.
Recent studies have revealed that the innate arm of the
immune system plays a bigger role in the onset and regulation
of inflammatory processes during ATB than previously thought.
ROS-generating cells are central to Mtb-induced inflammatory
response; and that they are main actors of relevant cell
death processes (i.e., apoptosis, necrosis, pyroptosis, necroptosis,
pyronecrosis, NETosis, and autophagy) that influence TB disease
progression [reviewed byMohareer et al. (25)], suggests that their
activity contributes considerably to destructive immunity to Mtb
infection. The aim of this review is to provide an update on the
importance of neutrophils during ATB and to identify related
immune mediators associated with anti-TB treatment response
and lung damage.
TB-INDUCED INFLAMMATORY RESPONSE
Innate immune responses play a central role in the pathology of
infectious and inflammatory diseases including acute abdominal
inflammation (26), cancers (27, 28) and respiratory tract
disorders (29, 30). Phagocytic cells (i.e., neutrophils and
macrophages) are the predominant components of this response
in TB (17). In collaboration with inflammatory mediators like
cytokines (31) and proteases, they are key contributors to the
host interaction with Mtb, in a process which generally ends with
the destruction of the pathogen and resolution of inflammation
(32). In many cases, however, the inflammatory response is
relatively ineffective and can lead to destruction of host tissues
as reviewed by Fullerton and Gilroy (33). Such an unwanted
scenario is characterized by a constant influx of inflammatory
mediators and innate immune cells to the site of infection with
progressive deterioration of the affected tissue. The end result
is the formation of tuberculous granulomas whose structure,
immune/pathogen cell balance (34), and intrinsic T-cell activity
(35) ultimately determine the degree of formation of tissue
lesions (36).
Defining and Assessing Lung Impairment
In order to understand the role of neutrophils in lung pathology,
we need consensus on structural versus functional impairment.
There are currently no international guidelines describing how
to classify levels of structural impairment following TB as well
as identifying TB sequelae in general (37). ATB is increasingly
further classified with respect to disease severity into the extent
of functional and/or structural lung damage, however, a decisive
classification of TB patient pathology has not been reached at this
time. Nonetheless, certain criteria have allowed the severity of
active pulmonary TB to be determined following assessment of
impaired pulmonary function via spirometry testing (38) and the
observation of lesions and/or lung cavities through chest x-rays
(CXR) and computed tomography (CT) (39).
Structural lung abnormalities determined by x-ray or
computed topography (CT) scores have been observed to
correlate to a degree with lung function in pulmonary TB (40).
Reports also suggest that functional pulmonary impairment at
diagnosis only begins to improve significantly several months
after the end of successful TB therapy (4, 40). Saldana et al.
observed that CXR abnormalities are inversely proportional to
and more reliable than spirometry evaluations when assessing
severity of lung impairment in cured ATB patients (41). An
even earlier study by Plit et al. showed that the change in CXR
score (pre- vs. post-treatment) is the most reliable predictor
of the severity of functional lung impairment in ATB: here
too, an inverse proportionality was observed between CXR
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TABLE 1 | Clinical studies assessing TB sequelae.
References Study site Study type and design
post-treatment
commencement
ATB sample
size, n
Nature of residual lung
impairment
Associated
inflammatory
response
Ngahane et al. (46) Cameroon Cross-sectional
Includes HIV+
269 Structural (CXR lesions) and
Functional (dyspnoea and
spirometry)
No
Ralph et al. (13) Indonesia Longitudinal [Baseline (BL),
6M & over 6M]
Includes HIV+
200 Structural (CXR score of lesions
and cavitation) and Functional
(dyspnoea, SGRQ, spirometry)
No
Kumar et al. (47) India Longitudinal (BL & 6M)
No HIV+ cases
Part of larger study involving
patients with co-morbidities
24 Structural (cavitation; no
CXR-score)
Yes
Ravimohan et al.
(48)
USA Prospective (over 6M)
All TB/HIV+
14 Functional (spirometry) Yes (MMPs)
Pasipanodya et al.
(11)
USA Longitudinal (BL, 6M & over
6M)
Includes HIV+
177 Functional (SGRQ and
spirometry)
No
Plit et al. (42) South Africa Longitudinal (BL & 6M)
Includes HIV+
76 Structural (CXR score of lung
infiltrates) Functional (spirometry)
Yes (c-reactive
protein (CRP) and
serum α1-protease
inhibitor (α1-PI)
Cole et al. (43) South Africa Cross-sectional
Includes HIV+
55 Functional (SGRQ and
spirometry)
No
Patil and Patil (44) India Longitudinal (6M, 9M, &
12M)
No HIV+ cases
118 Functional (dyspnoea and
spirometry)
No
Hnizdo et al. (4) South Africa Retrospective (BL-−375M)
Includes HIV+
2,599 Functional (spirometry) No
Maguire et al. (45) Indonesia Longitudinal (BL, 2M, & 6M)
Includes HIV+
115 Functional (dyspnoea, SGRQ,
spirometry)
No
Saldana et al. (41) Mexico Cross-sectional
Includes HIV+
127 Functional (Spirometry) and
Structural (CXR abnormalities)
No
Vecino et al. (14) USA Longitudinal (BL, 6M, & over
6M)
123 Functional (Spirometry) No
Chushkin et al. (3) Russia Prospective (Over 12M)
Undetermined HIV status
214 Functional (Spirometry) No
scores and forced expiratory volume (FEV1; a spirometric
parameter) (42). These suggest that monitoring variations in
structural impairment during TB therapy is essential (or at least
of significant added value) when attempting to determine the
extent of TB sequelae. However, whilst most relevant clinical
studies have generally attempted to monitor ATB-linked signs
of TB sequelae via assessment of dyspnoea and disrupted
lung function by spirometry (3, 4, 11, 14, 43–45), fewer cases
have accounted for both structural and functional damage (13,
41, 42, 46), and none focussing on the former exclusively
(see Table 1). Relevant follow-up parameters, where available
(especially involving longitudinal cohort studies), appear to have
relied on the researchers’ study objective and understanding of
TB sequelae—variably assessing different forms of pulmonary
damage, lung rehabilitation and even treatment responses but
not the potential inflammatory triggers of these events as the
Ravimohan group’s latest review hints (49). This is probably
owing to absence of a referential guideline as mentioned above.
At this time, a few studies: Ravimohan et al. (48) and Plit
et al. (42) have assessed severity of lung impairment in ATB
in relation to the expression of inflammatory mediators: matrix
metalloproteinases (MMPs) in the former and; serum c-reactive
protein (CRP), serum α1-protease inhibitor (α1-PI) and urine
cotinine in the latter. To account for these limitations, a
multisite trial is currently underway to monitor host-pathogen
and socioeconomic factors that influence the development of
pulmonary sequelae in ATB patients (50).
EVIDENCE OF NEUTROPHIL IMPACT ON
DESTRUCTIVE TB INFLAMMATION
Neutrophilia and Hyperinflammation
Polymorphonuclear neutrophils are the most abundant type of
white blood cells and play a central role in the immune response
to bacterial pathogens (51). The protective activity of neutrophils
in TB infection is observed during granuloma formation where
mycobacteria are phagocytosed from infected macrophages by
oxidative killing (52).
Frontiers in Immunology | www.frontiersin.org 3 May 2020 | Volume 11 | Article 962
Muefong and Sutherland Neutrophils in TB Inflammation
Previous work indicates that the levels of granulocytes
(neutrophils and eosinophils) in circulation are higher in patients
with ATB disease than those with latent TB infection (LTBI);
with levels decreasing significantly following successful TB
treatment (53). It has also been demonstrated that neutrophilia
independently associates not only with increased risk of cavity
formation and lung tissue damage (54), but also mortality
in patients undergoing TB therapy (55), suggesting that the
neutrophil count in tuberculosis positively correlates with
bacillary load and disease outcome. Recently, Leem et al.
(56) monitored inflammatory markers in TB patients and
found that the neutrophil counts and neutrophil to lymphocyte
ratios (NLR) were decreased following a 6-months anti-TB
drug therapy compared to baseline. These results hint that
inflammation might be resolved only following the 6-month
treatment completion, suggesting that progress to chronic
inflammation and development of pulmonary lesions is a
silent process potentially mediated by secondary products of
inflammatory response whose activity persist in tissue long after
mycobacterial clearance.
Despite the lack of a consensus on neutrophil classification,
varying attributes: granule content (cytotoxic species/enzyme
concentration), density (low or normal density granulocytes),
nuclear segmentation [banded or (hyper)-segmented], tumor
suppressive/enhancing functions (N1/N2), to surface antigen
expression [CD177 (7, 57, 58); CD16, CD62L and CD11b]
and cytokine/chemokine secretion levels have been associated
to disease and immunoregulation [reviewed in Hellebrekers
et al. (59), Perobelli et al. (60), and Wang (61)]. It is therefore
arguable that a combination of these attributes could constitute a
neutrophil profile suggestive of disease severity at an early stage as
well as anticipated development of sequalae if chronic conditions
(in TB potentially) were to be established. However, given the vast
discrepancies in markers, experimental conditions and disease
models investigated by previous studies as described in the
reviews cited above, these functional differences in neutrophil
subsets will not constitute a focus here. Nevertheless, the severity
of ATB is linked to neutrophilia as discussed above; but also
a specific hyperactivated profile of the circulating neutrophils;
which has predominantly been associated with immature
banded (or non-segmented) neutrophils (8). Interestingly, the
bulk of neutrophil cytotoxic (and antibacterial) molecules are
concentrated in their granules. Hence, neutrophil degranulation
and exocytosis: processes requiring phosphatidylinositol 3-
kinase, (PI3-K) (62); are closely related to the severity of
neutrophil-mediated inflammation. We therefore anticipate that
a potential neutrophil bio-signature of ATB would encompass
enhancement/inhibition of some specific chemokines and
increased neutrophil-specific enzyme concentrations. In fact,
a recent review by Leisching (7) exposes the regulatory role
of PI3-K on enhanced neutrophil mobility and hyperactivity
and; the effect on neutrophil-driven TB inflammation. This
hyperactivity is equally suggested to be at play in chronic
periodontis where it is associated with increased migratory
capacity as well as pro-inflammatory cytokine (IL-8, TNF, and
IL-1, notably) production by circulating neutrophils (63). Taken
together, neutrophil relative abundance (in circulation and at
infection sites) and cytokine/enzyme release are potentially major
agents of hyperinflammatory conditions observed in ATB.
The mechanisms responsible for this inflammatory response
mainly result from three neutrophil functions: oxidative burst,
necrosis and NETosis.
Oxidative Burst Capacity
Although neutrophils have the capacity to protect against
Mtb infection, if left uncontrolled their collective activity may
produce pathogenic effects through different functions (64).
One such phagocytic function is oxidative burst, which is the
release of reactive oxygen species (ROS) mainly by neutrophils
and to a lesser extent, macrophages during phagocytosis, a
process which is mediated by nicotinamide adenine dinucleotide
phosphate (NADP) oxidase (65). This antibacterial activity
is performed by a myeloperoxidase system composed mainly
of reduced NADP (NADPH2), reduced glutathione (GSH),
azide, cyanide, thiocyanate, Tapazole, thiourea, cysteine,
ergothioneine, thiosulfate, reduced nicotinamide adenine
dinucleotide (NADH2), and tyrosine (66).
GSH levels have been shown to reduce significantly in
PMBCs and red blood cells isolated from tuberculosis patients
compared to healthy controls (67), while increased GSH
levels are reported to enhance T-cell capacity to inhibit Mtb
growth inside macrophages (68). Also, ROS produced by
neutrophils during oxidative burst have been reported to
drive Mtb-induced necrosis; which in turn promotes Mtb
growth (69). It has also been suggested that rapid assessment
of individual neutrophil oxidative burst capacity could
distinguish patients at risk of excessive immune responses
and thus could potentially guide therapy (70). Hence,
correlating neutrophil oxidative burst capacity with GSH
and/or NADPH2 levels in TB patients may provide avenues for
novel host-directed therapies.
Neutrophil Extracellular Traps (NETs)
In-vitro studies by Brinkmann (71) revealed that neutrophil
activation with lipopolysaccharide (LPS), interleukin 8 or
phorbol myristate acetate (PMA) led to the release of cell
components, which form an extracellular fibril matrix called
neutrophil extracellular traps (NETs). These components are
proteins [namely neutrophil elastase (NE) and myeloperoxidase
(MPO)], DNA and chromatin-derived fibers; which destroy
bacteria extracellularly (71, 72). This process, NETosis, is a
powerful neutrophil-mediated response to a range of infections
but also acts as a double-edged sword during inflammatory
diseases (73). Interestingly, neutrophils can sense pathogen size
and can produce more NETs in presence of larger pathogens
like Mycobacterium bovis (74). Although aggregated NETs are
reported to degrade neutrophil-derived inflammatory mediators
in an attempt to resolve inflammation (75), NETs also stimulate
unwanted immune reactions and trigger tissue injury (73, 76).
In TB pathogenesis, Mtb is reported to induce the formation
of NETs, which trap Mycobacteria in vitro but are unable to
kill them (77). This may be partially explained by the fact
that expression of enzyme systems such as those required
in inflammatory pathways [i.e., to degrade proteins within
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the phagolysosome (e.g., MPO) and for the phagocytic burst,
NADPH-oxidase complex and the generation of ROS] are
suppressed (78). Furthermore, these Mtb-induced NETs are also
associated with macrophage activation in humans (79) and
could thus help elucidate specific inflammatory mechanisms
of lung damage in TB pathogenesis. Indeed, a recent study
by De Melo et al. revealed high levels of citrullinated H3—
a common NET marker—in serum samples from TB patients
with extensive pulmonary damage (54). Although this marker
is usually measured in combination with others (i.e., MPO
and NE) to specifically identify NETs, this study suggests that
NET formation is centrally linked with severe lung tissue
damage in TB patients and could be implicated in subsequent
pulmonary pathology.
Neutrophil-mediated lung injury is not just restricted to
Tuberculosis. For example, excessive neutrophil recruitment and
NETosis was linked to acute lung injury in a mouse model of
Influenza pneumonitis (80). Additionally, more recent studies
reveal that reduced neutrophil recruitment into infected tissue
promotes resolution of inflammation (81). Hence, monitoring
NETosis and neutrophil-associated inflammatory mediators
within inflamed tissue could be useful in developing therapeutic
targets against chronic inflammatory conditions like TB (72).
Metalloproteinases in Destructive TB
Immunity
A group of molecules increasingly associated with excessive
lung inflammation is the matrix metalloproteinases (MMPs). In
the case of cystic fibrosis, which results in loss of pulmonary
architecture, Pardo et al. described in a review (82) the essential
role played by MMPs in modifying the tissue microenvironment
and modulating cell signaling through their ability to degrade
constituents of the extracellular matrix. Although the origin of
most MMPs cannot be directly linked to neutrophils, MMP-9 is
known to be secreted rapidly by neutrophils in whole blood from
healthy volunteers following proinflammatory stimulus (83) and
is suggested to facilitate transmembrane neutrophil migration
(84); also reviewed in Pardo et al. (82). Similar to MMP-9, MMP-
8 synthesis in ATB patients is also suspected to be of neutrophil
origin (85). In effect, Ravimohan et al. (48) assessed the role of
MMPs on TB-immune reconstitution inflammatory syndrome
and observed increased MMP-8; whilst MMP-2, -3 and -9 levels
reduced (MMP-1 did not vary significantly) in patients with
impaired lung function post-TB cure following antiretroviral
therapy. MMP-1 and MMP-8 have previously been shown to
correlate with pulmonary tissue damage (PTD) in patients with
ATB (85, 86) while MMP-14 has been shown to play a central
role in TB pathogenesis by provoking collagen degradation and
regulating monocyte migration (87). Interestingly, a more recent
study by DeMelo et al. found lower levels of serumMMP-8 in TB
patients with severe PTD showing no radiological improvement
after 60 days of anti-TB treatment (54). Whether this change in
trend is related to plasma vs serum or due to the presence/absence
of HIV infection is unknown, however, the latter observation
is inconsistent with that from the previous studies reported
above and suggests that MMP regulation in TB patients might
differ between the circulation and the lung as well as in the
presence of coinfection. Nonetheless, de Melo et al. (54) did
find higher MMP-1 levels in these patients compared to those
with improved chest-x rays. Hence, whilst there is clearly a role
for MMPs in TB-linked tissue damage, more detailed studies,
with assessment of coinfections, are required to ascertain which
MMPs are predominant mediators. This will help to determine
potential host-directed therapeutic strategies.
Furthermore, a few clinical studies onmajor TB comorbidities
have recently emerged. One shows that sputum levels of MMP-
1, -2, -3 and -9 are higher in HIV negative TB patients than in
TB healthy controls (HC) and HIV positive TB patients with a
correlation found between the degree of chest x-ray inflammation
and both MMP-1 and MMP-3 levels in HIV negative TB patients
(88). Moreover, the clinical severity of TB is known to increase
in TB patients with diabetes mellitus (DM). Kumar et al. have
shown that circulatory levels of MMP-1, -2, -3, -8, and -13 in
these patients decrease following successful TB treatment and
that MMP-1 (in sputum) and MMP-1, -2, -3, -9, and -12 levels
(in serum) were higher in patients with more severe structural
lung damage at baseline (47) as determined from chest x-rays.
These findings suggest that MMPs (MMP-1, -2, -3, -8,
and -9, particularly) may promote tissue injury following
Mtb infection. Hence, monitoring the correlation of these
particular MMPs together with the downregulation of other
neutrophil-related inflammatory proteins and pro-inflammatory
cytokines associated with intracellular killing pathways during
TB infection would increase our understanding of the active
inflammatory pathways which enhance susceptibility to
development of PIAT and subsequent sequelae. Importantly,
natural regulation of MMP activity is performed by tissue
inhibitors of metalloproteinases (TIMPs). The levels of TIMPs
have not yet been monitored in TB patients; an aspect of TB
research which should be addressed for optimal understanding
of inflammatory mechanisms involved in development and host
control of TB-related PTD.
NEUTROPHIL-RELATED TB HDT
With increasing cases of co-infections, co-morbidities, drug
resistance; as well as the cost associated with the relatively
long standard antibiotic TB-treatment, new treatment regiments
like host directed therapies (HDT) could complement existing
Mtb-targeted approaches. Meanwhile biomarkers for efficiently
identifying and treating TB disease progressors at an early
stage are being actively researched (89), those that could single
out individuals who develop unresolving inflammation-induced
lung damage are still greatly under-investigated. This means
that research on HDTs should ideally focus on diagnosis and
prevention of the latter long-lasting condition as well. Recent
reviews have highlighted various established as well as promising
host directed adjuvant therapies against the development of TB
disease (90), TB-linked inflammation (91, 92) and lung damage
(93). Drugs that potentially inhibit pulmonary damage and/or
promote lung repair range from steroids to nonsteroidal anti-
inflammatory drugs, statins, metformin, dietary supplements,
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TNF blockers etc. (10). Of these, we observe that those
suppressing pro-inflammatory aspects of the disease appear
to be potent targets in preclinical and clinical trials. In fact,
Young et al. have recently reviewed current targets in TB
HDT with some of the most advanced ATB-relevant in clinical
trials being modulators of pro-inflammatory mediators which:
dampen inflammatory responses, curb immunopathology and
resolve lung damage (93). These include the phase 3 drugs:
cox-2 inhibitor (Meloxicam) and corticosteroids (Prednisolone
and Dexamethasone) amongst others. This HDT potential of
inflammatory mediators has also been addressed with inhibitory
effects on neutrophil recruitment (Ibuprofen) and neutrophil-
derived inflammatory mediators such as ROS and MPO as
reviewed by Dallenga et al. (94).
Also, a combination of the anti-inflammatory drug, zileuton
(an inhibitor of the synthesis of pro-inflammatory eicosanoid;
already approved against asthma) and prostaglandin E2
(95) is reported to reduce bacillary load and TB-induced
lung damage in mice. Statins are also interesting HDT
targets against destructive lung pathology following ATB
(96); with a promising phase 2 trial using pravastatin being
investigated in South Africa (ClinicalTrials.gov Identifier:
NCT03456102). Moreover, a phase 2b trial testing the effect
of atorvastatin against PIAT in patients with or without
HIV is about to begin in South Africa (ClinicalTrials.gov
Identifier: NCT04147286); underlining the potential of
these agents.
Potentially, some mediators of neutrophil function
(mentioned in previous sections) could provide suitable
HDT targets. Amongst others, these involve: vitamin D which is
reported to inhibit Mtb-induced expression of MMP-7 and−10
as well as MMP-9 gene expression, secretion and activity by
peripheral blood mononuclear cells (PBMCs) (97). Although the
authors reported that the latter inhibition occurs irrespective
of infection, MMP-9 is reported to be of neutrophil origin
and in-depth investigation may be warranted. Doxycycline is
also a known MMP-inhibitor which in TB-HIV co-infection
particularly, is shown to suppress the secretion of TNF, MMP-1
and−9 by primary human macrophages while reducing Mtb
growth in the guinea pig model of TB (98). Also, Allen et al.
reviewed the importance of considering GSH as HDT against TB
and TB/HIV co-infection (99). Furthermore, it is important to
note that N-acetylated proline glycine proline (ac-PGP) induces
neutrophil chemotaxis and neutrophil production of MMP-9
and IL-8 (100, 101) which has led this molecule to be suggested
as potential HDT-target against chronic neuroinflammatory
diseases (102) and cystic fibrosis (103); which result in
MMP activation and result in considerable tissue damage
like TB.
Besides these, calprotectin, a hetero-dimer made up of
proteins S100A8 and S100A9 is a mediator of inflammatory
responses and a potent diagnostic and HDT target against
inflammatory diseases (104). Actually, Gopal et al. (9) reported
that S100A8/A9 accumulates in TB-induced granulomas. The
authors showed that this accumulation was neutrophil-driven (in
humans) and the animal models they employed suggested an
association between S100A8/A9 and the degree of inflammation
and lung pathology during ATB. Recently, it has been shown
that these high levels of S100A8/A9 as well as an S100A8/A9-
mediated enhanced accumulation of neutrophils in lungs of mice
and macaques are associated with Mtb proliferation in chronic
TB disease (105). Both studies reveal a close interaction between
neutrophils and S100A8/A9 in ATB suggesting that neutrophils
and S100A8/A9, particularly could be targeted in TB HDT.
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
In conclusion, we believe that observation and monitoring
of neutrophil subsets and related inflammatory mediators is
important not only for studies aiming at developing novel
therapeutic targets against TB (72) but also for improved
estimation of host immuno-modulatory effects on the severity
of TB sequalae. It is foreseeable that the extent of long-term
pulmonary injury sustained and potentially resorbed following
TB therapy (irrespective of HIV coinfection) could be correlated
to a specific neutrophil function. It is also likely that ATB
patients who express a specific form of neutrophil-mediated
inflammatory response over the period from diagnosis through
treatment are more susceptible to developing chronic PIAT
than otherwise. A major challenge will be harmonizing the
categorization of disease severity (structural and functional)
to ease comparison between clinical studies. Moreover, we
believe that prediction of treatment response and residual
pulmonary impairment in future clinical studies would be made
more effective and reproduceable by evaluating inflammatory
responses as well as simultaneously monitoring variations in
pulmonary structure and function during and months after
treatment completion. Finally, prospective HDTs; which rely
on inflammatory mediators of neutrophil activity particularly,
should be investigated further.
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